Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2014; 20(45): 17227-17234
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17227
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17227
Ref. | Year | Study design | n (CMT/TACE) | Tumor stage | KPS | Child-Pugh Class (A/B/C) | Anticancer drug of TACE |
Chia-Hsien Cheng et al[25] | 2001 | Nonrandomized | 33 (17/16) | II, IIIA, IVA | ≥ 70 | 33/0/0 | doxorubicin, cisplatin, MMC |
Lan et al[24] | 2005 | Nonrandomized | 102 (42/60) | II, III | 10-Hydroxycamptothecine, DDP, 5-FU | ||
Li et al[23] | 2003 | Nonrandomized | 82 (41/41) | 50/32/0 | 10-Hydroxycamptothecine, 5-FU, MMC or ADM | ||
Liao et al[22] | 2010 | Randomized | 48 (24/24) | III, IV | 34/14/0 | 5-FU, DDP, ADM | |
Liu et al[21] | 2005 | Nonrandomized | 114 (54/60) | ≥ 70 | 83/31/0 | MMC, ADM, CBP | |
Shang et al[20] | 2007 | Nonrandomized | 76 (40/36) | T1-2N0M0 | ≥ 70 | 5-FU, DDP, ADM or MMC | |
Shim et al[19] | 2005 | Nonrandomized | 73 (38/35) | III, IVa | 65/8/0 | doxorubicin | |
Wu et al[18] | 2004 | Nonrandomized | 81 (41/40) | I, II | ≥ 70 | 55/26/0 | MMC, ADM, CBP or DDP |
Zeng et al[17] | 2004 | Nonrandomized | 203 (54/149) | 158/45/0 | 5-FU, DDP, MMC | ||
Zhao et al[16] | 2006 | Randomized | 96 (49/47) | T1N0M0, T2N0M0 | ≥ 70 | 96/0/0 | 10-Hydroxycamptothecine, DDP, 5-FU |
Ref. | Year | 1-yr survival | 2-yr survival | 3-yr survival | |||
TACE + 3D-CRT | TACE alone | TACE + 3D-CRT | TACE alone | TACE + 3D-CRT | TACE alone | ||
Chia-Hsien Cheng et al[25] | 2001 | 58.0% | 56.0% | ||||
Lan et al[24] | 2005 | 57.1% | 61.7% | 40.5% | 30.0% | 26.2% | 16.7% |
Li et al[23] | 2003 | 73.2% | 54.8% | 58.7% | 27.3% | 41.9% | 12.8% |
Liao et al[22] | 2010 | 74.0% | 50.0% | 30.0% | 14.0% | ||
Liu et al[21] | 2005 | 66.5% | 53.9% | 48.4% | 37.2% | 37.4% | 17.8% |
Shang et al[20] | 2007 | 78.0% | 50.0% | 60.0% | 32.0% | 34.0% | 18.0% |
Shim et al[19] | 2005 | 36.8% | 14.3% | ||||
Wu et al[18] | 2004 | 90.2% | 89.7% | 75.6% | 58.7% | 44.6% | 24.0% |
Zeng et al[17] | 2004 | 71.5% | 59.6% | 42.3% | 26.5% | 24.0% | 11.1% |
Zhao et al[16] | 2006 | 82.0% | 55.0% | 63.0% | 28.0% | 43.0% | 15.0% |
- Citation: Zou LQ, Zhang BL, Chang Q, Zhu FP, Li YY, Wei YQ, Guan YS. 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(45): 17227-17234
- URL: https://www.wjgnet.com/1007-9327/full/v20/i45/17227.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i45.17227